REFERENCES
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer 2015;136:E359-86.
3. Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015;4:36-54.
4. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
5. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86.
6. Arafa el-SA, Zhu Q, Shah ZI, Wani G, Barakat BM, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res 2011;706:28-35.
7. Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008;16:66-73.
8. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30.
9. Salehan MR, Morse HR. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 2013;70:31-40.
10. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009;9:307-19.
11. Lee C, Raffaghello L, Longo VD. Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resist Updat 2012;15:114-22.
12. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010;44:152-67.
13. Laurençot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 1997;72:1021-6.
14. Berger W, Elbling L, Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000;88:293-300.
15. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12:550-6.
16. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475-9.
17. Meschini S, Marra M, Calcabrini A, Monti E, Gariboldi M, et al. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol In Vitro 2002;16:389-98.
18. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995;1:578-82.
19. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, et al. Mediated silencing of nuclear factor erythroid-2–related factor 2 gene expression in non–small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-84.
20. Bachas S, Eginton C, Gunio D, Wade H. Structural contributions to multidrug recognition in the multidrug resistance (MDR) gene regulator, BmrR. Proc Natl Acad Sci U S A 2011;108:11046-51.
21. Ji L, Li H, Gao P, Shang G, Zhang DD, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One 2013;8:e63404.
22. Singh A, Wu H, Zhang P, Happel C, Ma J, et al. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 2010;9:2365-76.
23. Stockel B, Konig J, Nies AT, Cui Y, Brom M, et al. Characterization of the 5’-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison withthe multidrug resistance protein 3 (MRP3) gene. Eur J Biochem 2000;267:1347-58.
24. Xu S, Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL. Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol 2010;299:G126-35.
25. Wang X, Campos CR, Peart JC, Smith LK, Boni JL, et al. Nrf2 Upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood–spinal cord barriers. J Neurosci 2014;34:8585-93.
26. Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci 2006;27:501-17.
27. Xue F, Liu Z, Xu J, Xu X, Chen X, et al. Neferine inhibits growth and migration of gastrointestinal stromal tumor cell line GIST-T1 by up-regulation of miR-449a. Biomed Pharmacother 2019;109:1951-9.
28. Li XC, Tong GX, Zhang Y, Liu SX, Jin QH, et al. Neferine inhibits angiotensin II-stimulated proliferation in vascular smooth muscle cells through heme oxygenase-1. Acta Pharmacol Sin 2010;31:679-86.
29. Poornima P, Quency RS, Padma VV. Neferine induces reactive oxygen species mediated intrinsic pathway of apoptosis in HepG2 cells. Food Chem 2013;136:659-67.
30. Poornima P, Weng CF, Padma VV. Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest. Biofactors 2014;40:121-31.
31. Zhang X, Liu Z, Xu B, Sun Z, Gong Y, et al. Neferine, an alkaloid ingredient in lotus seed embryo, inhibits proliferation of human osteosarcoma cells by promoting p38 MAPK-mediated p21 stabilization. Eur J Pharmacol 2012;677:47-54.
32. Cao JG, Tang XQ, Shi SH. Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastroenterol 2004;10:3062-4.
33. Ai XH, Tang XQ, Liu YP, Liu HQ, Dong L. Effect of neferine on adriamycin-resistance of thermotolerant hepatocarcinoma cell line HepG2/thermotolerance. Ai Zheng 2007;26:357-60.
34. Tang XQ, Cao JG. Enhancement of cytotoxicity of anticancer drugs in vitro by neferine in MCF-7 cells. Chin J Modern Appl Pharmacy 2001;18:345-7.
35. Poornima P, Kumar VB, Weng CF, Padma VV. Doxorubicin induced apoptosis was potentiated by neferine in human lung adenocarcima, A549 cells. Food Chem Toxicol 2014;68:87-98.
36. Sivalingam KS, Paramasivan P, Weng CF, Viswanadha VP. Neferine potentiates the antitumor effect of cisplatin in human lung adenocarcinoma cells via a mitochondria-mediated apoptosis pathway. J Cell Biochem 2017;118:2865-76.
37. Deng G, Zeng S, Ma J, Zhang Y, Qu Y, et al. The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma. Sci Rep 2017;7:41616.
38. Baskaran R, Poornima P, Huang CY, Padma VV. Neferine prevents NF-kappaB translocation and protects muscle cells from oxidative stress and apoptosis induced by hypoxia. Biofactors 2016;42:407-17.
39. Baskaran R, Poornima P, Priya LB, Huang CY, Padma VV. Neferine prevents autophagy induced by hypoxia through activation of Akt/mTOR pathway and Nrf2 in muscle cells. Biomed Pharmacother 2016;83:1407-13.
40. Baskaran R, Priya LB, Kalaiselvi P, Poornima P, Huang CY, et al. Neferine from Nelumbo nucifera modulates oxidative stress and cytokines production during hypoxia in human peripheral blood mononuclear cells. Biomed Pharmacother 2017;93:730-6.
41. Lalitha G, Poornima P, Archanah A, Padma VV. Protective effect of neferine against isoproterenol-induced cardiac toxicity. Cardiovasc Toxicol 2013;13:168-79.
42. Priya LB, Baskaran R, Huang CY, Padma VV. Neferine ameliorates cardiomyoblast apoptosis induced by doxorubicin: possible role in modulating NADPH oxidase/ROS-mediated NFκB redox signaling cascade. Sci Rep 2017;7:12283.
43. Pereira-Caro G, Mateos R, Sarria B, Cert R, Goya L, et al. Hydroxytyrosyl acetate contributes to the protective effects against oxidative stress of virgin olive oil. Food Chem 2012;131:869-78.
44. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
45. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma. J Natl Cancer Inst 1999;91:1647-53.
46. Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 2009;47:1619-31.
47. Lario AP, García CB, Elizondo ME, Lobo C. Expression of proteins associated with multidrug resistance to chemotherapy in lung cancer. Arch Bronconeumol 2007;43:479-84. (in Spanish)
48. Przystupski D, Michel O, Rossowska J, Kwiatkowski S, Saczko J, et al. The modulatory effect of green tea catechin on drug resistance in human ovarian cancer cells. Med Chem Res 2019;28:657-67.
49. Chen YL, Yang TY, Wu CL, Chen KC, Hsu SL, et al. Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells. Chinese J Physiol 2016;59:331-47.
50. Zhang W, Zhou H, Yu Y, Li J, Li H, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. OncoTargets Ther 2016;9:3359-68.
51. Forman HJ, Maiorino M, Ursini F. Signaling functions of reactive oxygen species. Biochemistry 2010;49:835-42.
52. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009;15:3423-32.
53. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-84.
54. Chian S, Thapa R, Chi Z, Wang XJ, Tang X. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem Biophys Res Commun 2014;447:602-8.
